The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1515
ISSUE1515
February 27, 2017
Crisaborole (Eucrisa) for Atopic Dermatitis
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Crisaborole (Eucrisa) for Atopic Dermatitis
February 27, 2017 (Issue: 1515)
The FDA has approved crisaborole 2% ointment
(Eucrisa – Pfizer) for topical treatment of mild to
moderate atopic dermatitis in patients ≥2 years old. It
is the first phosphodiesterase type-4 (PDE4) inhibitor
to be approved in the US for this...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.